RFG Advisory’s TherapeuticsMD TXMD Stock Holding History

RFG Advisory’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-206	Closed	-$11K	–	411
2020 Q1	$11K	Buy	+206	New	+$20.4K	﹤0.01%	347

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RFG Advisory's TXMD Position: Q2 2020 in Review

RFG Advisory sold out of TherapeuticsMD (TXMD) in Q2 2020, closing a stake of 206 shares — an estimated $11K sold.

RFG Advisory first reported a position in TXMD in Q1 2020 and held it in 1 quarter. The position peaked at $11K in Q1 2020. 149 funds tracked by Wall St. Rank hold TXMD as of Q2 2020.

RFG Advisory reported no remaining TherapeuticsMD position as of Q2 2020 after selling out during the quarter.
RFG Advisory sold 206 TherapeuticsMD shares in Q2 2020, an estimated $11K.
RFG Advisory first reported a position in TherapeuticsMD in Q1 2020 and held it in 1 quarter.
RFG Advisory's TherapeuticsMD position peaked at $11K in Q1 2020.
149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2020.

Based on RFG Advisory's 13F filing for Q2 2020, filed 3 Aug 2020.